Howard Streicher

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology · 2018 · 716 citations · Full text

Oncology, Ipilimumab Treatment, Clinical Trials +8

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy et al. · New England Journal of Medicine · 2016 · 588 citations · Full text

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2022 · 402 citations · Full text

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Van K. Morris, Mohamed E. Salem, Halla Nimeiri et al. · The Lancet Oncology · 2017 · 383 citations

Medicine, Immune Checkpoint Inhibitor, Surgery +4

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

Melinda S. Merchant, Matthew Wright, Kristin Baird et al. · Clinical Cancer Research · 2015 · 317 citations · Full text